BRAF Kinase Inhibitors Overview

BRAF Kinase Inhibitors

• Dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) are examples of BRAF kinase inhibitors.
• BRAF kinase inhibitors target the BRAF enzyme, a mutated enzyme that contributes to the growth of tumor cells.
• Monitoring blood cell counts (CBC), liver function tests (LFTs), and serum electrolytes is important for patients taking BRAF kinase inhibitors.
• Cardiovascular status should be monitored during treatment with BRAF kinase inhibitors.
• Patients should be monitored for signs of deep vein thrombosis (DVT) or pulmonary embolism (PE).
• Patients should be monitored for signs of bleeding.
• Hypersensitivity reactions are a potential side effect of BRAF kinase inhibitors.
• Skin lesions should be assessed in patients taking BRAF kinase inhibitors.
• Patients should be monitored for vision changes or eye pain.
• Encorafenib users should avoid grapefruit and grapefruit juice.
• Vemurafenib users should wear sunscreen and avoid sun exposure.
• BRAF kinase inhibitors can increase the risk of new skin malignancies.
• Patients should immediately notify their healthcare provider of any suspicious lesions.
• Patients should immediately notify their healthcare provider if they experience bleeding, liver dysfunction, changes in heart rhythm, eye pain, visual changes, fever, or thromboembolism.
• Patients taking vemurafenib should immediately stop the medication and contact their healthcare provider if they experience an allergic reaction or severe skin reaction.

This quiz covers essential information on BRAF kinase inhibitors such as Dabrafenib, Encorafenib, and Vemurafenib. It includes details on monitoring and potential side effects associated with these drugs. Understand the significance of monitoring blood counts, liver function, and managing hypersensitivity reactions.